Inspire Medical Systems (NYSE:INSP) Upgraded at Freedom Capital

Inspire Medical Systems (NYSE:INSP) was upgraded by research analysts at Freedom Capital to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

INSP has been the subject of several other research reports. Mizuho lowered their price target on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Piper Sandler lowered shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $85.00 to $55.00 in a research report on Tuesday, May 5th. JPMorgan Chase & Co. reduced their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Stifel Nicolaus decreased their target price on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, Zacks Research lowered shares of Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Inspire Medical Systems currently has an average rating of “Hold” and a consensus target price of $81.05.

Inspire Medical Systems Trading Up 3.3%

INSP opened at $46.95 on Tuesday. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 10.46, a PEG ratio of 4.60 and a beta of 0.71. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03. The stock has a fifty day moving average price of $44.71 and a 200 day moving average price of $62.53.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts forecast that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP bought a new stake in Inspire Medical Systems during the fourth quarter valued at about $203,929,000. Wasatch Advisors LP boosted its stake in Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after purchasing an additional 110,288 shares during the period. Morgan Stanley grew its holdings in Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after buying an additional 809,121 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after buying an additional 907,694 shares during the last quarter. Finally, State Street Corp increased its position in Inspire Medical Systems by 2.3% in the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after buying an additional 22,843 shares during the period. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.